Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice

Immunol Lett. 2005 Apr 15;98(1):161-5. doi: 10.1016/j.imlet.2004.11.003. Epub 2004 Nov 28.

Abstract

A newly synthesized compound, YM-90709, 2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline, was previously reported to specifically inhibit the binding of interleukin-5 (IL-5) to its receptor (R) on human eosinophils. In this study, the intravenous injection of YM-90709 inhibited antigen-induced infiltration of eosinophils into the bronchoalveolar lavage fluid (BALF) of BDF1 mice, with an ED(50) value of 0.050mg/kg. Anti-murine IL-5 monoclonal antibody (mAb) also inhibited the infiltration of eosinophils with an ED(50) value of 0.035mg/kg. These results indicate that YM-90709, which is a novel IL-5R antagonist, inhibits antigen-induced eosinophil recruitment into the airway, the same as anti-IL-5 mAb does.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens / immunology
  • Cell Movement / drug effects*
  • Cell Movement / immunology
  • Eosinophils / drug effects*
  • Eosinophils / immunology
  • Indoles / pharmacology*
  • Mice
  • Quinoxalines / pharmacology*
  • Receptors, Interleukin / antagonists & inhibitors*
  • Receptors, Interleukin-5
  • Respiratory System / drug effects*
  • Respiratory System / immunology

Substances

  • 2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo(7,8)indolizino (2,3-b)quinoxaline
  • Antigens
  • Indoles
  • Quinoxalines
  • Receptors, Interleukin
  • Receptors, Interleukin-5